A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

Takao Tsuji; Takeshi Shimizu; Keiko Sasaki; Kentaro Tsukamoto; Hideyuki Arimitsu; Sadayuki Ochi; Toshiyasu Shimizu; Koki Taniguchi; Masatoshi Noda; Paola Neri; Hiroshi Mori

doi:10.1016/j.vaccine.2008.02.034

A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

Takao Tsuji, Takeshi Shimizu, Keiko Sasaki, Kentaro Tsukamoto, Hideyuki Arimitsu, Sadayuki Ochi, Toshiyasu Shimizu, Koki Taniguchi, Masatoshi Noda, Paola Neri, Hiroshi Mori

Microbiology

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

Original language	English
Pages (from-to)	2092-2099
Number of pages	8
Journal	Vaccine
Volume	26
Issue number	17
DOIs	https://doi.org/10.1016/j.vaccine.2008.02.034
Publication status	Published - 16-04-2008

All Science Journal Classification (ASJC) codes

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.02.034

Cite this

@article{9ac061d082784d688a83a8125f43228b,

title = "A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2",

abstract = "Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.",

author = "Takao Tsuji and Takeshi Shimizu and Keiko Sasaki and Kentaro Tsukamoto and Hideyuki Arimitsu and Sadayuki Ochi and Toshiyasu Shimizu and Koki Taniguchi and Masatoshi Noda and Paola Neri and Hiroshi Mori",

note = "Funding Information: This work was supported by the Japan Society for the Promotion of Science (JSPS) (18590440), and for the Open Research Center's Project of Fujita Health University from the Ministry of Education, Culture, Sports, Science and Technology of Japan.",

year = "2008",

month = apr,

day = "16",

doi = "10.1016/j.vaccine.2008.02.034",

language = "English",

volume = "26",

pages = "2092--2099",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "17",

}

TY - JOUR

T1 - A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

AU - Tsuji, Takao

AU - Shimizu, Takeshi

AU - Sasaki, Keiko

AU - Tsukamoto, Kentaro

AU - Arimitsu, Hideyuki

AU - Ochi, Sadayuki

AU - Shimizu, Toshiyasu

AU - Taniguchi, Koki

AU - Noda, Masatoshi

AU - Neri, Paola

AU - Mori, Hiroshi

N1 - Funding Information: This work was supported by the Japan Society for the Promotion of Science (JSPS) (18590440), and for the Open Research Center's Project of Fujita Health University from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

PY - 2008/4/16

Y1 - 2008/4/16

N2 - Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

AB - Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

UR - https://www.scopus.com/pages/publications/41549158210

UR - https://www.scopus.com/inward/citedby.url?scp=41549158210&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.02.034

DO - 10.1016/j.vaccine.2008.02.034

M3 - Article

C2 - 18387720

AN - SCOPUS:41549158210

SN - 0264-410X

VL - 26

SP - 2092

EP - 2099

JO - Vaccine

JF - Vaccine

IS - 17

ER -

A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this